Biopharmaceutical News and Research

RSS

UT Health San Antonio leads effort for developing oral vaccine against chlamydia

The study of a novel oral vaccine that could protect against chlamydia infection has been awarded approximately $11 million in National Institutes of Health funding over five years through a cooperative agreements research project grant, known as a U01 grant.

9 May 2024

Gyros Protein Technologies introduces Gyrolab Generic Rodent ADA Kit Reagents to support preclinical immunogenicity assessment

...

From Gyros Protein Technologies AB 3 May 2024

Sphere Fluidics appoints Dale Levitzke as Chief Executive Officer

...

From Sphere Fluidics 2 May 2024

CN Bio raises $21 million USD in first close of Series B investment round

Bayland Capital and founding shareholder, CN Innovations Holdings Ltd, to invest $10 M and $5.5 M, respectively. Investment will expand product development and scaling of the organization to meet increased demand for Organ-on-a-Chip (OOC) solutions.

23 Apr 2024

MD Anderson and CureVac collaborate on mRNA-based cancer vaccines

The University of Texas MD Anderson Cancer Center and CureVac N.V. today announced a co-development and licensing agreement to develop novel mRNA-based cancer vaccines.

16 Apr 2024

$Hip fracture survival rates in seniors worse than many cancers, study shows$

Hip fracture survival rates in seniors worse than many cancers, study shows

A new article in JBMR Plus, published by Oxford University Press, indicates that patient survival rates after hip or other bone fractures can be very poor.

9 Apr 2024

New technique reveals insights into gut cell dynamics during inflammation

Cells within the intestines perform various roles including nutrient absorption, sensing, and maintaining homeostasis.

2 Apr 2024

Ubiquigent and Debiopharm enter agreement to support USP1 inhibitor programme for Debio 0432

Project will be a demonstration of how Ubiquigent’s DUB-centric platform can support the development of DUB inhibitors all the way from discovery through to clinical development.

From Ubiquigent Limited 26 Mar 2024

ArgusEye introduces AugaOne to accelerate downstream bioprocess development

ArgusEye, a provider of innovative sensor solutions for real-time monitoring of biological systems, today announced the introduction of the AugaOne™ sensor system.

21 Mar 2024

Precision unveiled: Exploring the cutting-edge of analytical weighing with Cubis® II ultra-high resolution balances

This interview explores the cutting edge of analytical weighting with Cubis® II ultra-high resolution balances.

From Sartorius Lab Instruments GmbH & Co. KG 20 Mar 2024

Biden is right. The US generally pays double that of other countries for Rx drugs.

It's well documented that Americans pay high prices for health care. But do they pay double or more for prescriptions compared with the rest of the world? President Joe Biden said they did.

6 Mar 2024

BioCina and NovaCina forge strategic alliance to offer biologics developers integrated drug substance and drug product solutions

BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organisation (CDMO), and NovaCina Pty Ltd., a global fill-and-finish CDMO, announced a strategic partnership to provide integrated drug substance and drug product solutions for biologics developers.

From BioCina Pty Ltd. 29 Feb 2024

MD Anderson acquires cell therapy safety technology from Bellicum Pharmaceuticals

The University of Texas MD Anderson Cancer Center today announced it has acquired certain assets from Bellicum Pharmaceuticals, Inc. related to the CaspaCIDe switch platform and the GoCAR platform.

22 Feb 2024

Novel synthetic antibiotic effective against drug-resistant bacteria

A new antibiotic created by Harvard researchers overcomes antimicrobial resistance mechanisms that have rendered many modern drugs ineffective and are driving a global public health crisis.

15 Feb 2024

CARB-X awards $1.8 million to Visby Medical to develop a portable rapid PCR test for gonorrhea

Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) will award up to US$1.8 million to biotechnology company, Visby Medical, to develop a portable rapid polymerase chain reaction (PCR) diagnostic to detect the presence of the pathogen that causes gonorrhea, Neisseria gonorrhoeae (NG), and its susceptibility to ciprofloxacin, a former frontline oral antibiotic that can no longer treat resistant NG.

9 Feb 2024

Enterprise Therapeutics closes £26 million ($33.1 million) Series B follow-on financing

Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering from respiratory disease, today announced that it has closed a £26 million ($33.1 million USD) Series B follow-on financing round, led by Panakes Partners.

From Enterprise Therapeutics Ltd 31 Jan 2024

Balancing efficacy and safety: The challenges of mRNA drugs and vaccines in modern medicine

Researchers analyzed the toxicity concerns and advancements in mRNA therapeutics, focusing on their cellular toxicity, reactogenicity, and distribution, and discussed the challenges and benefits of mRNA research.

24 Jan 2024

New blood test technique raises hopes for more sensitive and earlier cancer diagnosis

Tumors constantly shed DNA from dying cells, which briefly circulates in the patient's bloodstream before it is quickly broken down. Many companies have created blood tests that can pick out this tumor DNA, potentially helping doctors diagnose or monitor cancer or choose a treatment.

18 Jan 2024

£30M clinical study will enhance the understanding of NASH cirrhosis

The most extensive clinical study into liver cirrhosis ever conducted worldwide has been announced by Newcastle University, University of Edinburgh and leading research-driven global biopharmaceutical company, Boehringer Ingelheim.

8 Jan 2024

Scripps Research commemorates 100 years of innovation in science and medicine

Scripps Research, a nonprofit biomedical institute ranked one of the most influential in the world for its impact on innovation, will celebrate its 100-year history throughout 2024.

5 Jan 2024